Li-wu Fu, Ph.D., Professor, Doctoral Supervisor. Prof. Fu obtained his PhD in the field of Cancer Pharmacology from the Sun Yat-sen University and carried out his doctoral research in South Carolina Medical University from 1999 to 2001. 

Prof. Fu’s field of expertise includes anticancer drug pharmacology, molecular mechanism of anticancer drugs and individual cancer chemotherapy. In recent years, he mainly focused on the study of molecular mechanism of anti-cancer drugs, drug resistance of cancer cells (especially multidrug resistance), the innate resistance of cancer stem cells and the individual cancer chemotherapy. For the excellent work in the research of “Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells”, Prof. Fu’s team gained the first prize of “Chinese Anti-Cancer Association (CACA) Science and Technology Award” (Ranked first) and the second prize of “Institute of Higher Education Outstanding Scientific Research Achievements Award” (Natural Science Award) in 2011. 

As the leader of the research group, he has won the provincial and ministerial level scientific and technological awards for several times, including the “Outstanding young scientific and technological talents award from Ministry of Health”, the “Servier outstanding young workers Pharmacology Award” and the “Ding Ying Science Award” in 2011. 

Prof. Fu has presided over and successfully completed more than 40 key research projects on national, provincial and ministerial scale and horizontal fund projects. 

More than 200 research papers have been published and up to 100 papers have been published in high-quality SCI journals, including Cancer Res (6 articles), Oncotarget, Mol Med, Cell Cycle, Eur J Cancer, Mol Cancer Ther, Birth J Parmacol, Biochem Pharmacol , Mol Pharmacol etc. and 10 invention patents have been attained.

1. Screening of tumor multi-drug resistance reversal agents and mechanism research 

2. Development and research of novel chemotheraputic drugs.

3. Developing tumor chemosensitivity testing system to realize individualized chemotherapy

For information on Professor Fu's laboratory, click here and select: Research on anticancer drugs.

1982-1987 M.D. Degree from Guangdong Medical and Pharmaceutical College, Guangdong, China.

1990-1993 Master degree from Sun Yat-Sen University of Medical Sciences, Guangdong, China. 

1993-1996 Ph.D. degree from Sun Yat-Sen University of Cancer Center, Guangdong, China.

1999-2002 Postdoctoral Associate at South Carolina Medical University, United States.

1．Wang XK, He JH, Xu JH, Ye S, Wang F, Zhang H, Huang ZC, To KK, Fu LW*. Afatinib Enhances the Efficacy of Conventional Chemotherapeutic Agents by Eradicating Cancer Stem-like Cells. Cancer Res. 2014 Jun 27. [Epub ahead of print] (IF:9.28)

2. Zhu H, Zhang H, Jin F, Fang M, Huang M, Yang CS, Chen T, Fu L*, Pan Z*. Elevated Orai1 expression mediates tumor-promoting intracellular Ca2+ oscillations in human esophageal squamous cell carcinoma. Oncotarget. 2014 Jun 15;5(11):3455-71. (IF:6.63)

3. Zhang H, Wang YJ, Zhang YK, Wang DS, Kathawala RJ, Patel A, Talele TT, Chen ZS, Fu LW*. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Cancer Lett. 2014 Aug 1;350(1-2):61-8. (IF:5.02)

4. Hong J, Liu Z, Zhu H, Zhang X, Liang Y, Yao S, Wang F, Xie X, Zhang B, Tan T, Fu L*, Nie J*, Cheng C*. The tumor suppressive role of NUMB isoform 1 in esophageal squamous cell carcinoma. Oncotarget. 2014 Jun 26. [Epub ahead of print] (IF:6.63)

5. Liu KJ, He JH, Su XD, Sim HM, Xie JD, Chen XG, Wang F, Liang YJ, Singh S, Sodani K, Talele TT, Ambudkar SV, Chen ZS, Wu HY, Fu LW*. Saracatinib (AZD0530) is a potent modulator of ABCB 1-mediated multidrug resistance in vitro and in vivo. Int J Cancer. 2013 Jan 1;132(1):224-35. (IF=6.20)

6. Hu YP, Tao LY, Wang F, Zhang JY, Liang YJ, Fu LW*. Secalonic acid D reduced the percentage of side populations by down-regulating the expression of ABCG2. Biochem Pharmacol. 2013 Jun 1;85(11):1619-25. (IF=4.65)

7. Zhao XQ, Xie JD, Chen XG, Sim HM, Zhang X, Liang YJ, Singh S, Talele TT, Sun Y, Ambudkar SV, Chen ZS, Fu LW*. Neratinib Reverses ATP-Binding Cassette B1-Mediated Chemotherapeutic Drug Resistance In Vitro, In Vivo, and Ex Vivo. Mol Pharmacol. 2012; 82(1):47-5

8. (IF=4.78)8. Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, Bates SE, Peng XX, Abraham I, Ambudkar SV, Talele TT, Fu LW*, Chen ZS*. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res. 2011; 71(8):3029-41. (IF:9.28)

9.Wang F, Liang YJ, Wu XP, Chen LM, To KK, Dai CL, Yan YY, Wang YS, Tong XZ, Fu LW*. Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia. Eur J Cancer. 2011; 47(13):1990-9. (IF=5.54)

10. Yan YY, Zheng LS, Zhang X, Chen LK, Singh S, Wang F, Zhang JY, Liang YJ, Dai CL, Gu LQ, Zeng MS, T Talele T, Chen ZS, Fu LW*. Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu. Mol Pharm. 2011; 8(5):1687-97. (IF=5.4)

11. Shi Z, Tiwari AK, Patel AS, Fu LW*, Chen ZS*. Roles of sildenafil in enhancing drug sensitivity in cancer. Cancer Res. 2011; 71(11):3735-8. (IF:9.28) (Review)

12. Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, Tao LY, Zhang CZ, Dai CL, Tiwari AK, Ma XX, To KK, Ambudkar SV, Chen ZS, Fu LW*. Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters. Cancer Res. 2010; 70(20):7981-91. (IF:9.28)

13. Zhang JY, Tao LY, Liang YJ, Yan YY, Dai CL, Xia XK, She ZG, Lin YC, Fu LW*. Secalonic acid D induced leukemia cell apoptosis and cell cycle arrest of G(1) with involvement of GSK-3beta/beta-catenin/c- Myc pathway. Cell Cycle. 2009; 8(15):2444-50. (IF=5.0)

14. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby Jr. CR, Huang Y， Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW*. Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2. Cancer Res. 2008; 68(19):7905-7914. (IF:9.28)

15.Yan YY, Su XD, Liang YJ, Zhang JY, Shi CJ, Lu Y, Gu LQ, Fu LW*. Emodin azide methyl anthraquinone derivative triggers mitochondrial-dependent cell apoptosis involving in caspase-8-mediated Bid cleavage. Mol Cancer Ther. 2008; 7(6):1688-97. (IF=6.11)

16. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW*, Ambudkar SV, Chen ZS*. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 2007; 67(22):11012-20. (IF:9.28)

 

Last updated on: August, 2014